TATTON Ph Ib Expansion Cohort: Osimertinib plus Savolitinib for Pts with EGFR-Mutant MET-Amplified NSCLC after Progression on Prior EGFR-TKI

被引：26
|
作者：
Ahn, M. [1 ]
Han, J. [2 ]
Sequist, L. [3 ]
Cho, B. C. [4 ]
Lee, J. S. [5 ]
Kim, S. [6 ]
Su, W. [7 ]
Tsai, C. [8 ]
Yang, J. C. [9 ]
Yu, H. [10 ]
Horn, L. [11 ]
Lee, K. [12 ]
Haddad, V. [13 ]
Frigault, M. [14 ]
Ahmed, G. [13 ]
Yang, L. [15 ]
Ghiorghiu, D. [13 ]
Oxnard, G. [16 ]
机构：
[1] Samsung Med Ctr, Seoul, South Korea
[2] Natl Canc Ctr, Ctr Lung Canc, Goyang, South Korea
[3] Massachusetts Gen Hosp, Boston, MA 02114 USA
[4] Yonsei Canc Ctr, Med Oncol, Seoul, South Korea
[5] Seoul Natl Univ, Bundang Hosp, Seoul, South Korea
[6] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[7] Natl Cheng Kung Univ Hosp, Tainan, Taiwan
[8] Taipei Vet Gen Hosp, Dept Chest Med, Taipei, Taiwan
[9] Natl Taiwan Univ Hosp, Taipei, Taiwan
[10] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[11] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[12] Taipei Med Univ, Shuang Ho Hosp, Taipei, Taiwan
[13] Astrazeneca, Cambridge, England
[14] Astrazeneca, Waltham, MA USA
[15] Astrazeneca, Shanghai, Peoples R China
[16] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
non-small cell lung cancer; EGFR-Mutant; MET-amplification;
D O I：
10.1016/j.jtho.2017.09.377
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA 09.03
引用
收藏
页码：S1768 / S1768
页数：1
相关论文
共 50 条
  • [41] Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer
    Piper-Vallillo, Andrew J.
    Halbert, Brian T.
    Rangachari, Deepa
    Kobayashi, Susumu S.
    Costa, Daniel B.
    JTO CLINICAL AND RESEARCH REPORTS, 2020, 1 (04):
  • [42] Pharmacokinetic/Pharmacodynamic Analysis of Savolitinib plus Osimertinib in an EGFR Mutation- Positive, MET-Amplified Non-Small Cell Lung Cancer Model
    Jones, Rhys D. O.
    Petersson, Klas
    Tabatabai, Areya
    Bao, Larry
    Tomkinson, Helen
    Schuller, Alwin G.
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (05) : 679 - 690
  • [43] INSIGHT 2: Tepotinib plus Osimertinib in EGFR-Mutant NSCLC with Resistance to 1st-Line Osimertinib due to MET Amplification
    Smit, E.
    Felip, E.
    Karachaliou, N.
    Ellers-Lenz, B.
    Wu, Y. -L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S36 - S36
  • [44] Tepotinib plus osimertinib for EGFR-mutant NSCLC with resistance to first-line osimertinib due to MET amplification (METamp): INSIGHT 2
    Wu, Y-L.
    Dooms, C.
    Nadal, E.
    Raskin, J.
    Demedts, I.
    Mazieres, J.
    Wislez, M.
    Abdul Shukor, S.
    Tho, L. M.
    Wang, C-C.
    Viteri, S.
    Le, X.
    How, S. H.
    Tan, D.
    Takeda, M.
    Veillon, R.
    Karachaliou, N.
    Ellers-Lenz, B.
    Smit, E. F. F.
    ANNALS OF ONCOLOGY, 2021, 32 : S1036 - S1036
  • [45] Tepotinib plus Osimertinib in EGFR-mutant NSCLC with MET Amplification Following 1L Osimertinib: INSIGHT 2 Primary Analysis
    Kim, T. M.
    Guarneri, V.
    Jye, V. P.
    Khaw, L. B.
    Yang, J. -J.
    Wislez, M.
    Huang, C.
    Kin, L. Chong
    Mazieres, J.
    Tho, L. M.
    Hayashi, H.
    Nhung, N.
    Chia, P. L.
    De Marinis, F.
    Raskin, J.
    Zhou, Q.
    Finochhiaro, G.
    Le, X.
    Tan, D.
    Brutlach, S.
    O'Brate, A.
    Adrian, S.
    Berghoff, K.
    Ellers-Lenz, B.
    Karachaliou, N.
    Wu, Y. -L.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S94 - S94
  • [46] Tepotinib plus osimertinib in EGFR-mutant NSCLC with MET amplification following first-line osimertinib: INSIGHT 2 primary analysis
    Le, Xiuning
    Kim, Tae Min
    Guarneri, Valentina
    Voon, Pei Jye
    Lim, Boon Khaw
    Yang, Jinji
    Wislez, Marie
    Huang, Cheng
    Liam, Chong Kim
    Mazieres, Julien
    Lye Mun Tho
    Hayashi, Hidetoshi
    Nguyen Nhung
    Chia, Puey Ling
    De Marinis, Fillippo
    Raskin, Jo
    Zhou, Qinghua
    Finochhiaro, Giovanna
    Tan, Daniel
    Brutlach, Sabine
    O'Brate, Aurora
    Adrian, Svenja
    Berghoff, Karin
    Ellers-Lenz, Barbara
    Karachaliou, Niki
    Wu, Yi-Long
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [47] Tepotinib plus Osimertinib in EGFR-mutant NSCLC with MET Amplification Following 1L Osimertinib: INSIGHT 2 Primary Analysis
    Kim, Tae Min
    Guarneri, Valentina
    Voon, Pei Jye
    Lim, Boon Khaw
    Yang, Jin-ji
    Wislez, Marie
    Huang, Cheng
    Liam, Chong Kin
    Mazieres, Julien
    Tho, Ye Mun
    Hayashi, Hidetoshi
    Nhung Nguyen
    Chia, Puey Ling
    de Marinis, Filippo
    Raskin, Jo
    Zhou, Qinghua
    Finocchiaro, Giovanna
    Le, Xiuning
    Tan, Daniel
    O'Hara, Richard M., Jr.
    Brutlach, Sabine
    O'Brate, Aurora
    Adrian, Svenja
    Berghoff, Karin
    Ellers-Lenz, Barbara
    Karachaliou, Niki
    Wu, Yi-Long
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E38 - E38
  • [48] Atezolizumab plus albumin paclitaxel-based regimens is an optional treatment for EGFR-mutant patients with SCLC transformation after EGFR-TKI
    Wang, J.
    Wang, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S58 - S59
  • [49] First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease
    Xu, Qinghua
    Liu, Hui
    Meng, Shuyan
    Jiang, Tao
    Li, Xuefei
    Liang, Shixiong
    Ren, Shengxiang
    Zhou, Caicun
    JOURNAL OF CANCER, 2019, 10 (02): : 522 - 529
  • [50] INSIGHT2: Tepotinib plus osimertinib in pts with EGFR-mutant NSCLC and acquired resistance to 1L osimertinib due to METamp
    Morise, Masahiro
    Sakai, Hiroshi
    Kato, Terufumi
    Tokito, Takaaki
    Takeda, Masayuki
    Tanaka, Hiroshi
    Chikamori, Kenichi
    Daga, Haruko
    Kijima, Takashi
    Ohashi, Kadoaki
    Karachaliou, Niki
    Ellers-Lenz, Barbara
    Wu, Yi-Long
    ANNALS OF ONCOLOGY, 2021, 32 : S309 - S309
12345